Xenon Pharmaceuticals
XENE
245 hedge funds and large institutions have $3.78B invested in Xenon Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 81 increasing their positions, 74 reducing their positions, and 22 closing their positions.
127% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 22
12% more funds holding
Funds holding: 219 → 245 (+26)
12% more capital invested
Capital invested by funds: $3.39B → $3.78B (+$398M)
9% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 74
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.1% less ownership
Funds ownership: 109.36% → 109.26% (-0.1%)
34% less call options, than puts
Call options by funds: $36.4M | Put options by funds: $54.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$48.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$34.5M |
| 3 |
Barclays
London,
United Kingdom
|
+$20.6M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$18.5M |
| 5 |
Two Sigma Investments
New York
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$74.8M |
| 2 |
CC
Commodore Capital
New York
|
-$37.8M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$35M |
| 4 |
Millennium Management
New York
|
-$31.5M |
| 5 |
Holocene Advisors
New York
|
-$29.2M |
XENE Hedge Fund Activity: Q4 2025 in Review
245 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2025, worth a combined $3.78B — up 12% from $3.39B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new XENE positions and 22 closed out — a net gain of 28 holders — while 81 added to existing stakes and 74 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $48.5M. The largest seller was Braidwell, cutting an estimated $74.8M.
- 245 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2025, up from 219 in Q3 2025.
- Funds reported $3.78B of Xenon Pharmaceuticals stock for Q4 2025, up 12% quarter-over-quarter.
- 50 funds opened new Xenon Pharmaceuticals positions in Q4 2025 and 22 closed out, a net change of +28 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2025 was Wellington Management Group, an estimated $48.5M added.
- The largest Xenon Pharmaceuticals seller in Q4 2025 was Braidwell, an estimated $74.8M sold.
Based on aggregated 13F filings for Q4 2025.